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 2 
Summary  19 
 20 
In some low and middle-income countries, 10-20% of patients presenting with a persistent 21 
cough have TB. Once TB is excluded, health service provision for alternative diagnoses is 22 
limited. We prospectively studied patients with two negative sputum Xpert-MTB/RIF® assays 23 
presenting to a TB clinic in The Gambia. 108/239 patients did not have TB. 65/102 (6 drop-24 
outs) had alternative diagnoses established, 24.6% non-respiratory. 37/102 had no 25 
diagnosis, of these 27.0% were HIV-1 positive, 37.8% had a history of TB and 24.3% smoked. 26 
We highlight need for general health service integration with TB platforms and exploration 27 
of not-TB patients with chronic respiratory symptoms. 28 
 29 
 30 
 31 
  32 
  33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
 3 
Introduction    70 
 71 
A leading cause of NCD-related mortality is chronic respiratory disease, causing an estimated 72 
3.8 million deaths in 2015.1 While TB is still a major problem, in some low- and middle- 73 
income countries (LMIC), only 10-20% of patients presenting with a persistent cough have 74 
TB.2 Thus there is a large proportion of patients with respiratory symptoms of unknown 75 
aetiology.  76 
 77 
The advent of the Xpert MTB/RIF®, nucleic acid amplification tests, are improving early 78 
diagnosis providing same-day results, with a sensitivity of 89% compared to sputum culture 79 
as gold standard.3 Importantly, this increased sensitivity means that those who test negative 80 
are less likely to have active TB.  81 
 82 
TB clinics have been ill equipped both in terms of experience and equipment to effectively 83 
diagnose and treat other respiratory diseases, despite WHO strategy highlighting this 84 
(Practical Approach to Lung Health (PAL)).4  We generated preliminary data in The Gambia 85 
exploring the potential of TB platforms to capture, investigate and manage chronic 86 
respiratory symptoms in patients classified as not having TB.  87 
 88 
Materials and Methods  89 
We prospectively recruited all patients from a TB research clinic who did not meet the 90 
inclusion criteria (at least one sputum sample positive for TB by Xpert MTB/RIF assay) for TB 91 
sequel, a study exploring the impact of TB on lung function. 5 All patients had a chest 92 
radiograph and rapid HIV tests (Alere Determine HIV-1/2 Ab/Ag), with laboratory serology 93 
confirmation if positive (4th generation DiaSorin Liaison XL Murex HIV Ab/Ag assay,6 Hexagon 94 
HIV1/2, Geenius HIV-1/2 confirmation assay) and investigations as clinically indicated (e.g. 95 
Full blood count, Urea and electrolytes, Liver function tests, ECG, Echocardiography, pleural 96 
aspirate, Peak Expiratory Flow Rate, Sputum TB Culture and/or microbiology). All patients 97 
had two and four week follow-ups minimum, extended according to clinical need. Asthma 98 
diagnosis was based on peak expiratory flow rate diary in patients presenting with audible 99 
wheeze and a history of more than three symptomatic episodes annually. Diagnoses of 100 
bacterial pneumonia were based on suggestive clinical features and chest radiograph 101 
infiltrates (resolving following antibiotic therapy). Heart failure was based on consistent 102 
clinical features and echocardiography (reduced ejection fraction, <50%). Serial renal 103 
function testing (eGFR <15ml/min/1.73m2) classified Chronic Renal Failure.  104 
 105 
Results  106 
Between September 2017 and July 2018, 239 patients with a chronic cough (> 2weeks) and 107 
any of night sweats, fever, weight loss, malaise or chest pain, were screened for TB. Fulfilling 108 
the inclusion criteria for TB Sequel, 114 patients had Xpert positive sputum results. The 109 
other 125 (52.3%) were Xpert 50.4% (n=63) or Xpert-Ultra 49.6% (n=62) negative on spot 110 
and early morning sputa (routine use of Xpert-Ultra was implemented in clinic mid-study). 111 
Of these 125 patients, 17 were classified as TB on clinical and radiological grounds (Table 1). 112 
The remaining 108 (45.1%) were classified as not having TB. These not TB patients were 113 
significantly older, heavier, less likely to be male and less likely to smoke than TB patients 114 
(sputum Xpert positive and Xpert negative clinical TB group) (Table 1).  115 
 116 
The 108 (45.1%) not TB patients included four deaths and six drop-outs. Of these 55% 117 
(60/108) received antibiotics (non-fluoroquinolone) for presumed bacterial infections, 118 
providing a future target for community antimicrobial stewardship. Excluding drop-outs 119 
none of the 102 developed clinical or radiological signs of TB during a median of 2 months 120 
 4 
(range 1-6 months) follow-up. Diagnoses were established in 65/102 (63.7%) not-TB patients 121 
(Table 2). The majority of these were acute respiratory conditions (75.3%) followed by 122 
cardiovascular (20%) and renal disease (3.1%), with one (1.5%) presumed haematological 123 
malignancy (Table 2).   124 
 125 
The percentages of HIV-1-infected patients in the Xpert positive group (n=114), Xpert 126 
negative clinical TB group (n=17) and not-TB group (n=108) were 8.7%, 41.2% and 11.1% 127 
respectively. The HIV positivity rate did not significantly differ between the sputum Xpert 128 
positive TB patients and the not TB patients.  129 
 130 
The diagnosis remained unknown in 37/102 (36.3%) not-TB cases. A high proportion of these 131 
(10/37; 27.0%) were new HIV-1 diagnoses, 14/37 (37.8%) had a past history of TB and 9/37 132 
(24.3%) smoked. 133 
 134 
Discussion 135 
Nearly half of all patients presenting to a TB clinic did not have a final diagnosis of TB and 136 
thirty-six per cent had no alternative diagnosis made using limited in-country diagnostics. Of 137 
these, many were HIV-1 positive, had past histories of TB and smoking, providing insights 138 
into potential disease aetiology. While the differential includes infections such as non-139 
tuberculous mycobacteria (NTM) and chronic pulmonary aspergillosis (CPA),7 it is likely that 140 
many represent NCDs, e.g. COPD or bronchiectasis. Better radiology (e.g. CT scans) and 141 
pathogen diagnostic facilities8 in future studies should aim to characterise this group further. 142 
Occupational and environmental air pollutants should also be taken in to account as data 143 
from Asia highlights.9  144 
 145 
The HIV-1 positivity rate in the not-TB group was seven-fold higher than the estimated 146 
population rate in The Gambia (1.6%).10 This is a striking finding in patients who not only do 147 
not have TB, but also lack other obvious HIV-associated opportunistic infections (e.g. acute 148 
bacterial pneumonia). Our findings come from secondary care and may not be 149 
representative of community rates, but do support WHO guidance of offering HIV testing to 150 
all patients suspected of having TB, not just those with confirmed TB. This is important, even 151 
in countries with relatively low prevalence, such as The Gambia. 152 
 153 
Our study was pragmatically performed in the context of routinely available care in The 154 
Gambia, thus has a number of limitations. More sophisticated diagnostics were unavailable 155 
(formal diagnoses of COPD werent possible). Routine culture of smear-negative TB patients 156 
is not standard practice in TB programmes in The Gambia and due to resource constraints it 157 
was only possible to perform culture on 24 not-TB participants. Although no one in this 158 
group developed active TB, it is possible that some patients may have had NTM lung disease 159 
or developed active TB post follow-up.  160 
 161 
A decade post-PAL strategy, services afforded to not-TB patients with chronic respiratory 162 
symptoms remain in their infancy in Sub Saharan Africa. As efforts are enhanced to find and 163 
treat TB using highly sensitive assays, the opportunity to build NCD pathways integrated into 164 
TB platforms still exists. These preliminary findings suggest further context-specific 165 
implementation research focusing on not-TB screen-outs is needed to enable application of 166 
the PAL strategy.  167 
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TB  
GeneXpert positive  
(n=114) 
Clinical TB 
GeneXpert negative 
(n=17) 
 
Not TB 
(n=108) 
 
 
TB Versus 
Not TB  
p value* 
 
Age in years  32 (26-40)  
 
42 (35-52) 40 (28-47)  
 
0.0331 
Male:Female Ratio  2.5:1 2.2:1 1:1 0.0087 
HIV-1 positive  10 (8.7%) 7 (41.2%) 12 (11.1%) ns 
Weight in kg  51 (46-58) 51 (43-58) 56 (49-64) 0.0015 
Former or current 
smoker  
46 (40.4%) 5 (29.4%) 24 (22.2%) 0.0091 
 
Past history of TB 
 
7 (6.1%) 
 
5 (29.4%) 
 
16 (14.8%) 
 
ns 
 
Deaths  
 
 
2 (1.8%) 
 
0 (0.0%) 
 
4 (3.7%) 
 
ns 
Table 1. Characteristics of all patients (n=239). All values are n (%), except age and weight 218 
where median (IQR) is shown. ns = not significant at threshold of p=0.05. 219 
 220 
* p values were calculated using Mann-Whitney U statistical comparison of unmatched pairs or 221 
chi square (and Fishers exact) Test as indicated.    222 
 223 
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 Diagnosis Unknown (n=37) Estab
HIV-1 Positive 10 (27.0%) 
Past history of TB  14 (37.8%) 
Former or current smoker  9 (24.3%) 
Deaths  Cause unknown  2 (5.4%) 
Presumed Lung Malignancy  - 
Haematological Malignancy  - 
Respiratory  Other bacterial or viral respiratory tract 
infection  
- 
Pneumonia  - 
Asthma  - 
Pleural effusion  - 
Lung abscess  - 
Lung malignancy  - 
Cardiovascular Heart failure  - 
Structural heart disease  - 
Ischaemic heart disease  - 
Renal Chronic renal failure  - 
Table 2 Characteristics of Not TB patients followed-up with established and 227 
unknown diagnoses. Patients lost to follow up have been excluded. 228 
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